Pacer Advisors Inc. Increases Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Pacer Advisors Inc. boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,742 shares of the company’s stock after purchasing an additional 1,729 shares during the quarter. Pacer Advisors Inc.’s holdings in IDEXX Laboratories were worth $6,943,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Massachusetts Financial Services Co. MA raised its holdings in shares of IDEXX Laboratories by 4.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 406,086 shares of the company’s stock valued at $205,163,000 after buying an additional 15,521 shares during the last quarter. Integrated Investment Consultants LLC raised its stake in IDEXX Laboratories by 48.4% during the 3rd quarter. Integrated Investment Consultants LLC now owns 650 shares of the company’s stock valued at $328,000 after acquiring an additional 212 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in IDEXX Laboratories by 4.8% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 73,477 shares of the company’s stock worth $37,122,000 after acquiring an additional 3,382 shares during the period. Citizens Financial Group Inc. RI increased its holdings in shares of IDEXX Laboratories by 26.4% in the third quarter. Citizens Financial Group Inc. RI now owns 853 shares of the company’s stock valued at $431,000 after purchasing an additional 178 shares during the period. Finally, Moors & Cabot Inc. purchased a new stake in shares of IDEXX Laboratories during the third quarter worth approximately $210,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of analyst reports. Piper Sandler reiterated a “neutral” rating and issued a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. JPMorgan Chase & Co. dropped their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Barclays reduced their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, Stifel Nicolaus dropped their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $552.38.

IDEXX Laboratories Price Performance

IDXX stock opened at $417.24 on Friday. The firm has a 50 day moving average of $460.86 and a 200-day moving average of $480.68. The company has a market cap of $34.17 billion, a price-to-earnings ratio of 40.24, a PEG ratio of 3.65 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. IDEXX Laboratories’s revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.53 earnings per share. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.